Akari Therapeutics will present a corporate overview and discuss its ADC pipeline during a live webcast on September 4, 2025.
Quiver AI Summary
Akari Therapeutics, an oncology biotechnology company focused on innovative antibody drug conjugates (ADCs) for cancer treatment, announced its participation in the Virtual Investor Closing Bell Series on September 4, 2025, at 4 PM ET. CEO Abizer Gaslightwala will present an overview of the company's unique payload platform and its pipeline of next-generation ADCs, aimed at targeting various cancer tumors. The event will include a live Q&A session, allowing investors to interact directly with the company. Akari's lead candidate, AKTX-101, utilizes its novel spliceosome modulator payload, PH1, which has shown promise in preclinical studies for inducing cancer cell death and has potential synergy with checkpoint inhibitors. A replay of the webcast will be available on the company's website shortly after the event.
Potential Positives
- Akari Therapeutics is participating in a prominent virtual event, potentially increasing visibility and engagement with investors and stakeholders.
- The company's lead candidate, AKTX-101, shows promising preclinical results, indicating significant activity and potential for prolonged survival in cancer treatment, which positions the company favorably in the oncology market.
- Akari's innovative approach with its novel payload, PH1, differentiates it from existing ADC therapies, enhancing the potential for breakthroughs in cancer treatment.
- The opportunity for live Q&A during the webcast allows for direct engagement and transparency with investors, fostering trust and interest in the company's developments.
Potential Negatives
- No significant negatives reported in the press release.
FAQ
What is the date and time of the Akari Therapeutics webcast?
The Akari Therapeutics webcast will be on Thursday, September 4, 2025, at 4:00 PM ET.
Who will be speaking at the Virtual Investor Closing Bell Series?
Abizer Gaslightwala, President and CEO of Akari Therapeutics, will be leading the discussion.
How can investors participate in the webcast?
Investors can submit questions live during the event for discussion and answers.
Where can I access the webcast replay?
The webcast replay will be available on Akari Therapeutics' website two hours after the live event for 90 days.
What is the focus of Akari Therapeutics' research?
Akari Therapeutics focuses on developing novel immuno-oncology antibody drug conjugates (ADCs) for cancer treatment.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$AKTX Insider Trading Activity
$AKTX insiders have traded $AKTX stock on the open market 7 times in the past 6 months. Of those trades, 7 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $AKTX stock by insiders over the last 6 months:
- ABIZER GASLIGHTWALA (CEO) has made 7 purchases buying 52,146 shares for an estimated $56,659 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$AKTX Hedge Fund Activity
We have seen 5 institutional investors add shares of $AKTX stock to their portfolio, and 7 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SABBY MANAGEMENT, LLC added 179,785 shares (+inf%) to their portfolio in Q2 2025, for an estimated $210,330
- HIGHTOWER ADVISORS, LLC added 79,236 shares (+inf%) to their portfolio in Q2 2025, for an estimated $92,698
- OMNIA FAMILY WEALTH, LLC removed 24,938 shares (-28.5%) from their portfolio in Q2 2025, for an estimated $29,174
- CATALINA CAPITAL GROUP, LLC removed 13,105 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $16,250
- NEWEDGE ADVISORS, LLC added 6,800 shares (+inf%) to their portfolio in Q2 2025, for an estimated $7,955
- EVERSOURCE WEALTH ADVISORS, LLC added 4,377 shares (+inf%) to their portfolio in Q2 2025, for an estimated $5,120
- UBS GROUP AG added 2,154 shares (+inf%) to their portfolio in Q2 2025, for an estimated $2,519
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$AKTX Analyst Ratings
Wall Street analysts have issued reports on $AKTX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Maxim Group issued a "Buy" rating on 07/18/2025
To track analyst ratings and price targets for $AKTX, check out Quiver Quantitative's $AKTX forecast page.
Full Release
Live moderated webcast on Thursday, September 4 th at 4:00 PM ET
Access the event here
BOSTON and LONDON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel immuno-oncology payload antibody drug conjugates (ADCs) for the treatment of cancer, today announced that it will participate in the Virtual Investor Closing Bell Series on Thursday, September 4, 2025 at 4:00 PM ET.
As part of the event, Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics will provide a corporate overview and discuss its innovative payload platform fueling a pipeline of next-generation ADCs designed with novel immuno-oncology payloads to address a wide range of cancer tumor targets. In addition to the moderated discussion, investors and interested parties will have the opportunity to submit questions live during the event. The Company will answer as many questions as possible in the time allowed.
The live video webcast will be available in the Investors section of the Company’s website ( akaritx.com ). A webcast replay will be available two hours following the live event and will be accessible for 90 days.
About Akari Therapeutics
Akari Therapeutics is an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs). The Company has developed its first novel payload, PH1, a spliceosome modulator designed to disrupt RNA splicing within cells. PH1 is highly differentiated in its mechanism of action against cancer cells from current ADC payloads that use Topoisomerase1 inhibitors or tubulin inhibitors. This splicing modulator has been shown in preclinical animal models to induce cancer cell death while activating immune cells to drive robust and durable activity. Using this novel payload, Akari has the ability to generate multiple ADC molecules based on the desired application to a range of cancer targets of interest. Akari’s lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and delivers its novel PH1 payload directly into the tumor. In preclinical studies, AKTX-101 has shown to have significant activity and prolonged survival, relative to ADCs with traditional payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors, as compared to appropriate controls. The Company is generating validating data on its novel payload PH1 to continue advancing its lead asset, as well as other undisclosed targets with this novel payload.
For more information about the Company, please visit www.akaritx.com and connect on X and LinkedIn .
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
[email protected]
